Literature DB >> 11991814

Identification of human mannose binding lectin (MBL) recognition sites for novel inhibitory antibodies.

Hui Zhao1, Nobutaka Wakamiya, Yasuhiko Suzuki, Matthew T Hamonko, Gregory L Stahl.   

Abstract

Mannose binding lectin (MBL) binding initiates activation of the lectin complement pathway. Recent studies from our laboratory have demonstrated that MBL-dependent complement activation mediates cellular injury following oxidative stress in vivo and in vitro. A panel of novel inhibitory monoclonal antibodies (MAbs) against MBL (e.g., MAb 3F8, 2A9, and hMBL1.2) has been developed that inhibit MBL binding and lectin pathway activation. Here, we further characterized the interactions of these MAbs and their Fab fragments to MBL. Whole MAbs or their Fab fragments bound to MBL with relatively high affinity. Fab fragments of 3F8 were functionally effective in inhibiting MBL-dependent complement activation, however, steric hindrance of MAb 2A9 was essential for inhibition of MBL-dependent complement activation. We identified the hinge region, and residues EDCVLLL within the carbohydrate recognition domain of MBL as the recognition sites for MAb 3F8 and 2A9, respectively. The interaction of MAbs (e.g., 3F8 and 2A9) to MBL was dependent on the conformation of their recognition sites. These findings demonstrate that MBL binding can be inhibited by at least two separate and independent mechanisms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11991814     DOI: 10.1089/15368590252917610

Source DB:  PubMed          Journal:  Hybrid Hybridomics        ISSN: 1536-8599


  11 in total

1.  Design of a complement mannose-binding lectin pathway-specific activation system applicable at low serum dilutions.

Authors:  M Harboe; P Garred; M S Borgen; G L Stahl; A Roos; T E Mollnes
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

2.  Mannose-binding lectin and its associated proteases (MASPs) mediate coagulation and its deficiency is a risk factor in developing complications from infection, including disseminated intravascular coagulation.

Authors:  Kazue Takahashi; Wei-Chuan Chang; Minoru Takahashi; Vasile Pavlov; Yumi Ishida; Laura La Bonte; Lei Shi; Teizo Fujita; Gregory L Stahl; Elizabeth M Van Cott
Journal:  Immunobiology       Date:  2010-03-04       Impact factor: 3.144

3.  Mannose-binding lectin-associated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis.

Authors:  Laura R La Bonte; Vasile I Pavlov; Ying S Tan; Kazue Takahashi; Minoru Takahashi; Nirmal K Banda; Chenhui Zou; Teizo Fujita; Gregory L Stahl
Journal:  J Immunol       Date:  2011-12-12       Impact factor: 5.422

4.  Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.

Authors:  Laura Evgin; Sergio A Acuna; Christiano Tanese de Souza; Monique Marguerie; Chantal G Lemay; Carolina S Ilkow; C Scott Findlay; Theresa Falls; Kelley A Parato; David Hanwell; Alyssa Goldstein; Roberto Lopez; Sandra Lafrance; Caroline J Breitbach; David Kirn; Harold Atkins; Rebecca C Auer; Joshua M Thurman; Gregory L Stahl; John D Lambris; John C Bell; J Andrea McCart
Journal:  Mol Ther       Date:  2015-03-25       Impact factor: 11.454

5.  MASP-1 and MASP-3 Bind Directly to Aspergillus fumigatus and Promote Complement Activation and Phagocytosis.

Authors:  Anne Rosbjerg; Reinhard Würzner; Peter Garred; Mikkel-Ole Skjoedt
Journal:  J Innate Immun       Date:  2021-03-29       Impact factor: 7.349

6.  Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury.

Authors:  Masayuki Ozaki; Yulin Kang; Ying Siow Tan; Vasile I Pavlov; Bohan Liu; Daniel C Boyle; Rafail I Kushak; Mikkel-Ole Skjoedt; Eric F Grabowski; Yasuhiko Taira; Gregory L Stahl
Journal:  Kidney Int       Date:  2016-07-01       Impact factor: 10.612

7.  The role of properdin in zymosan- and Escherichia coli-induced complement activation.

Authors:  Morten Harboe; Peter Garred; Julie K Lindstad; Anne Pharo; Fredrik Müller; Gregory L Stahl; John D Lambris; Tom E Mollnes
Journal:  J Immunol       Date:  2012-07-30       Impact factor: 5.422

8.  Genetically Determined MBL Deficiency Is Associated with Protection against Chronic Cardiomyopathy in Chagas Disease.

Authors:  Paola Rosa Luz; Márcia I Miyazaki; Nelson Chiminacio Neto; Marcela C Padeski; Ana Cláudia M Barros; Angelica B W Boldt; Iara J Messias-Reason
Journal:  PLoS Negl Trop Dis       Date:  2016-01-08

Review 9.  The alternative complement pathway revisited.

Authors:  Morten Harboe; Tom Eirik Mollnes
Journal:  J Cell Mol Med       Date:  2008-04-15       Impact factor: 5.310

10.  Platelet thrombus formation in eHUS is prevented by anti-MBL2.

Authors:  R I Kushak; D C Boyle; I A Rosales; J R Ingelfinger; G L Stahl; M Ozaki; R B Colvin; E F Grabowski
Journal:  PLoS One       Date:  2019-12-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.